Myelodysplasia: When to treat and how
- 30 June 2006
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 19 (2) , 293-300
- https://doi.org/10.1016/j.beha.2005.11.005
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 StudyJournal of Clinical Oncology, 2005
- Efficacy of Lenalidomide in Myelodysplastic SyndromesNew England Journal of Medicine, 2005
- First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).Blood, 2004
- Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.Blood, 2004
- A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromeBlood, 2003
- Effects of influenza vaccination on mortality among frail, community-living elderly patients: An observational studyAging Clinical and Experimental Research, 2003
- Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2002
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Special Clinical Concerns/ Problems in the Management of MDS and Sedondary Acute Myeloid LeukemiasPublished by Springer Nature ,2001
- Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of ageBlood, 2000